LRRC22 Inhibitors
LRRC22 inhibitors belong to a distinct chemical class that primarily targets leucine-rich repeat-containing 22 (LRRC22), a protein encoded by the LRRC22 gene. The LRRC22 protein is recognized for its involvement in various cellular processes, particularly its role in protein-protein interactions mediated by leucine-rich repeats (LRRs). These repeats are structural motifs characterized by tandem arrays of leucine residues, which contribute to the formation of a versatile scaffold for diverse protein interactions. LRRC22, as a member of the LRR family, exhibits a modular architecture that makes it an intriguing target for inhibition.
The inhibitors designed to modulate LRRC22 function typically interfere with the protein's ability to engage in specific interactions or disrupt its structural integrity. Researchers have explored various chemical scaffolds and molecular structures to develop potent LRRC22 inhibitors, aiming to elucidate the protein's biological functions and pave the way for potential applications in manipulating cellular pathways. Understanding the chemical properties and structural characteristics of LRRC22 inhibitors provides valuable insights into the intricacies of protein-protein interactions within cellular contexts. This knowledge contributes to the ongoing efforts in unraveling the complex molecular mechanisms associated with LRRC22, laying the foundation for further investigations into the broader implications of targeting this protein in various cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that suppresses cell growth and proliferation. If LRRC22 is involved in cellular growth pathways that are mTOR-dependent, Rapamycin would lead to a functional inhibition of LRRC22 by hindering the pathway necessary for its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that blocks the PI3K/Akt/mTOR pathway. If LRRC22 functions downstream of or in conjunction with PI3K signaling, LY294002 would indirectly inhibit LRRC22 activity by preventing signal transduction required for its function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor that specifically blocks MAPK/ERK pathway activation. If LRRC22 is regulated by or associated with the MAPK/ERK pathway, PD98059 would indirectly inhibit its activity by blocking the necessary signaling for LRRC22 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that interferes with stress-activated protein kinase pathways. If LRRC22 is activated or regulated by stress responses mediated through p38 MAPK, SB203580 would lead to decreased LRRC22 activity by inhibiting this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which is involved in inflammatory and apoptotic processes. If LRRC22 plays a role in these processes and is JNK-dependent, SP600125 would indirectly inhibit LRRC22 by preventing JNK signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
An irreversible inhibitor of PI3K. Similar to LY294002, if LRRC22 functions rely on PI3K signaling, Wortmannin would lead to inhibition of LRRC22 by blocking PI3K-dependent pathways. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that prevents the degradation of ubiquitinated proteins. If LRRC22 is regulated through proteasomal degradation, Bortezomib could lead to an accumulation of LRRC22 that may result in a negative feedback loop inhibiting its functional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Another MEK inhibitor that blocks the MAPK/ERK pathway. By the same mechanism as PD98059, if LRRC22 is associated with the MAPK/ERK pathway, U0126 would indirectly inhibit LRRC22 activity. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
A dual PI3K/mTOR inhibitor. By inhibiting both PI3K and mTOR pathways, Dactolisib could indirectly inhibit LRRC22 if its activity is dependent on signaling through these pathways. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
An Akt inhibitor that prevents Akt phosphorylation and activation. If LRRC22 is part of the PI3K/Akt pathway, Triciribine would lead to inhibition of LRRC22 by preventing Akt-mediated signaling events that are necessary for LRRC22's activity. | ||||||